{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T22:24:27Z","timestamp":1714429467476},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00105-018-4258-7","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T05:40:37Z","timestamp":1535089237000},"page":"901-907","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aktuelle Therapie der systemischen Sklerodermie"],"prefix":"10.1007","volume":"69","author":[{"given":"Nicolas","family":"Hunzelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,24]]},"reference":[{"issue":"9","key":"4258_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00105-003-0578-2","volume":"54","author":"G Bali","year":"2003","unstructured":"Bali G, Aberer E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54(9):845\u2013851","journal-title":"Hautarzt"},{"issue":"11","key":"4258_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s00105-014-3528-2","volume":"65","author":"D Belz","year":"2014","unstructured":"Belz D, Hunzelmann N, Moinzadeh P (2014) Digital ulcers in scleroderma. Hautarzt 65(11):944\u2013948","journal-title":"Hautarzt"},{"key":"4258_CR3","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B Coleiro","year":"2001","unstructured":"Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI et\u00a0al (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40:1038\u20131043","journal-title":"Rheumatology"},{"issue":"10","key":"4258_CR4","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, Fligelstone K, Gompels LL, Griffiths B, Herrick AL, Pang J, Parker L, Redmond A, van Laar J, Warburton L, Ong VH (2016) BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 55(10):1906\u20131910","journal-title":"Rheumatology"},{"issue":"10","key":"4258_CR5","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1136\/annrheumdis-2015-208024","volume":"75","author":"R Dobrota","year":"2016","unstructured":"Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O (2016) EUSTAR coauthors.A Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a\u00a0EUSTAR analysis. Ann Rheum Dis 75(10):1743\u20131748","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4258_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M et al (2013) EUSTAR (EULAR Scleroderma Trials and Research group). Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a\u00a0EUSTAR observational study. Ann Rheum Dis 72(7):1217\u20131220","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 86","key":"4258_CR7","first-page":"214","volume":"32","author":"N Hansi","year":"2014","unstructured":"Hansi N, Thoua N, Carulli M, Chakravarty K, Lal S et\u00a0al (2014) Consensus best practice pathway of the UK Scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol 32(Suppl 86):214\u2013221","journal-title":"Clin Exp Rheumatol"},{"key":"4258_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","volume":"8","author":"AL Herrick","year":"2012","unstructured":"Herrick AL (2012) The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 8:469\u2013479","journal-title":"Nat Rev Rheumatol"},{"key":"4258_CR9","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/art.39166","volume":"67","author":"AM Hoffmann-Vold","year":"2015","unstructured":"Hoffmann-Vold AM, Aal\u00f8kken TM, Lund MB, Garen T, Midtvedt \u00d8, Brunborg C, Gran JT, Molberg \u00d8 (2015) Predictive value of serial HRCT analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 67:2205\u20132212","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"4258_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH Hoogen van den","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a\u00a024 week randomized double-blind trial, followed by a\u00a024 week observational trial. Br J Rheumatol 35(4):364\u2013372","journal-title":"Br J Rheumatol"},{"key":"4258_CR11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","volume":"54","author":"M Hughes","year":"2015","unstructured":"Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B et\u00a0al (2015) Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology 54:2015\u20132024","journal-title":"Rheumatology"},{"key":"4258_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","volume":"47","author":"N Hunzelmann","year":"2008","unstructured":"Hunzelmann N, Genth E, Krieg T et\u00a0al (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47:1185\u20131192","journal-title":"Rheumatology"},{"key":"4258_CR13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/jdv.14458","volume":"31","author":"R Knobler","year":"2017","unstructured":"Knobler R, Moinzadeh P, Hunzelmann N et al (2017) European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J\u00a0Eur Acad Dermatol Venereol 31:1401\u20131424","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4258_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, Chwiesko S, Miniati I et al (2017) EULAR recommendations for the treatment of systemic sclerosis: a\u00a0report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"4258_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jaad.2003.08.026","volume":"50","author":"A Kreuter","year":"2004","unstructured":"Kreuter A, Breuckmann F, Uhle A, Brockmeyer N, von Kobyletzki G et al (2004) Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J\u00a0Am Acad Dermatol 50:740\u2013747","journal-title":"J Am Acad Dermatol"},{"key":"4258_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","volume":"1","author":"JS Lee","year":"2013","unstructured":"Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I et al (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. Lancet Respir Med 1:369\u2013376","journal-title":"Lancet Respir Med"},{"key":"4258_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"key":"4258_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/annrheumdis-2014-205897","volume":"75","author":"C Mihai","year":"2015","unstructured":"Mihai C, Landew\u00e9 R, van der Haijde D, Walker UA, Constantin PI et\u00a0al (2015) Digital ulcers predict a\u00a0worse disease course in patients with systemic sclerosis. Ann Rheum Dis 75:681\u2013686","journal-title":"Ann Rheum Dis"},{"key":"4258_CR19","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3899\/jrheum.131210","volume":"41","author":"L Mouthon","year":"2014","unstructured":"Mouthon L, Bussone G, Berezn\u00e9 A, No\u00ebl LH, Guillevin L (2014) Scleroderma renal crisis. J\u00a0Rheumatol 41:1040\u20131048","journal-title":"J Rheumatol"},{"key":"4258_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1055\/s-0031-1298798","volume":"137","author":"G Riemekasten","year":"2012","unstructured":"Riemekasten G, Hoffmann U, Sunderk\u00f6tter C, Weiss N, Kuhn A (2012) angiologisch-dermatologisch-rheumatologische DU-Expertenboard. Management of digital ulcers in patients with systemic sclerosis. Dtsch Med Wochenschr 137:34\u201340","journal-title":"Dtsch Med Wochenschr"},{"key":"4258_CR21","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","volume":"72","author":"M Roustit","year":"2013","unstructured":"Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696\u20131699","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4258_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5301\/jsrd.5000214","volume":"1","author":"AB Shreiner","year":"2016","unstructured":"Shreiner AB, Murray C, Denton CP, Khanna D (2016) Gastrointestinal manifestations of systemic sclerosis. J\u00a0Scleroderma Relat Disord 1(3):247\u2013256. \n                    https:\/\/doi.org\/10.5301\/jsrd.5000214","journal-title":"J Scleroderma Relat Disord"},{"key":"4258_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1183\/09059180.00005512","volume":"22","author":"JJ Solomon","year":"2013","unstructured":"Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G (2013) Scleroderma lung disease. Eur Respir Rev 22:6\u201319","journal-title":"Eur Respir Rev"},{"key":"4258_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA Jr. (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66:940\u2013944","journal-title":"Ann Rheum Dis"},{"key":"4258_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA et al (2018) Myeloablative Autologous stem-cell transplantation for severe Scleroderma. N\u00a0Engl J Med 378:35\u201347","journal-title":"N Engl J Med"},{"key":"4258_CR26","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et\u00a0al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N\u00a0Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"4258_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenylate versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:208","journal-title":"Lancet Respir Med"},{"key":"4258_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acr.22018","volume":"65","author":"T Tingey","year":"2013","unstructured":"Tingey T, Shu J, Smuczek J, Pope J (2013) Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 65:1460\u20131471","journal-title":"Arthritis Care Res"},{"key":"4258_CR29","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Laar Van","year":"2014","unstructured":"Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z et\u00a0al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a\u00a0randomized clinical trial. JAMA 311:2490\u20132498","journal-title":"JAMA"},{"key":"4258_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","volume":"120","author":"FM Wigley","year":"1994","unstructured":"Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr. et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199\u2013206","journal-title":"Ann Intern Med"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-018-4258-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T23:09:08Z","timestamp":1566601748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-018-4258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,24]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4258"],"URL":"https:\/\/doi.org\/10.1007\/s00105-018-4258-7","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,24]]},"assertion":[{"value":"24 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Hunzelmann gibt Interessenkonflikte durch Vortragshonorare von Actelion, Bayer, Boehringer, Pfizer, Roche an.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}